- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04804904
A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects
January 6, 2022 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Single Center, Phase I, Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of TQB3101 in Healthy Subjects
Evaluate the effect of food on the pharmacokinetics of TQB3101 in healthy subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Zhongshan Hospital of Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must be willing and able to give written informed consent by signing an IRB-approved Informed Consent Form prior to admission to this study;
- Subjects must be willing and able to communicate well, understand and follow the protocol required to complete the study;
- Males and females between 18 to 60 years of age
- Males and females with a body mass Index (BMI) range 19~26 kg/m2 inclusive, male subject not less than 50kg, female subject not less than 45kg。
- Male subjects must agree to use a medically acceptable method of contraception from Screening until 6 months after administration of the last dose of study drug
- Male subjects agrees not to donate sperm for at least 6 months after administration of the last dose of study drug
- Female subjects of non-childbearing potential measures, meeting at least one of the following criteria:①menorrhoeal for 12 months and FSH >40mIU/mL;② hysterectomy;③oophorectomy.
- Subjects who are healthy as determined by physical examination,vital signs, 12-Lead ECG and X-ray examination.
Exclusion Criteria:
- Subjects who have a history or presence of cardiovascular, neurological, endocrine, respiratory, hematological, immunological, psychiatric diseases or disorders that, could affect the conduct of the study or the absorption, metabolism or excretion of the study drug.
- Subjects who have a history of relevant drug hypersensitivity or atopic allergic disease history(asthma,urticaria, eczema dermatitis).
- Current or recent (within 6 months of study drug administration) gastrointestinal , liver and kidney disease that could impact upon the absorption of study drug.
- Any major surgery within 4 weeks of study drug administration .
- Subjects who consume more than 14 units of alcohol per week during 3 months before drug administration, taken any alcohol-containing products within 24 hours ,or subjects who test negative alcohol at screening and admission
- Smokers who smoked more than 5 cigarettes before study drug administration,or can not quit smoking during the study.
- Subjects who test positive for drugs of abuse.
- Subjects who have donated blood or have a blood loss(≥300mL)within the previous 3 months prior to first dosing.
- Subjects who used any drugs that change liver enzyme activity,such as inhibitors or inducers of CYP3A4, P-gp or BCRP within 28days;
- Subjects who used any drugs including over thePrescription drugs, counter medications ,vitamin products herbal preparations.
- Subjects who have taken a special diet (including grapefruit, etc.) or exercised vigorously in the 14 days ,or other factors affecting drug absorption, distribution, metabolism, and excretion
- Participated in drug clinical trials within 3 months before taking the study ;
- Subjects with laboratory abnormalities,or or white blood cell count, neutrophil cell count and the percentage of the platelet count below the normal limit.
- Positive test result for HIV antibodies.
- Positive test for treponema Antibodies hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab).
- Subjects who have acute disease or concomitant medication at the time of screening and/or admission.
- Subjects who consuming chocolate, any caffeine-rich or xanthine-rich food or drink 24 hours before.
- The PI considered other factors unfit to participate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQ-B3101: Fed + Fast
In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fed condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fasted condition on Day 1 of treatment period 2.
|
TQ-B3101 oral capsule
|
Experimental: TQ-B3101: Fast+Fed
In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fed condition on Day 1 of treatment period 2.
|
TQ-B3101 oral capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: pre-dosing on Day 1 up to 144 hours post-dosing
|
maximum concentration of the analyte in plasma
|
pre-dosing on Day 1 up to 144 hours post-dosing
|
Tmax
Time Frame: pre-dosing on Day 1 up to 144 hours post-dosing
|
Time to Reach the Maximum Observed Plasma Concentration (Cmax) of the analyte
|
pre-dosing on Day 1 up to 144 hours post-dosing
|
AUC0-t
Time Frame: pre-dosing on Day 1 up to 144 hours post-dosing
|
Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of the analyte
|
pre-dosing on Day 1 up to 144 hours post-dosing
|
AUC0-inf
Time Frame: pre-dosing on Day 1 up to 144 hours post-dosing
|
Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time of the analyte
|
pre-dosing on Day 1 up to 144 hours post-dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 20, 2021
Primary Completion (Actual)
June 15, 2021
Study Completion (Actual)
July 3, 2021
Study Registration Dates
First Submitted
March 16, 2021
First Submitted That Met QC Criteria
March 17, 2021
First Posted (Actual)
March 18, 2021
Study Record Updates
Last Update Posted (Actual)
January 21, 2022
Last Update Submitted That Met QC Criteria
January 6, 2022
Last Verified
March 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- TQ-B3101-I-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetic Study
-
AnHeart Therapeutics Inc.Completed
-
Pharmaceutical Productions Inc.National Institute on Drug Abuse (NIDA)CompletedNicotine Pharmacokinetic StudyUnited States
-
Poitiers University HospitalUnknownPharmacokinetic StudyFrance
-
AstraZenecaCompletedHealthy Volunteers Pharmacokinetic StudyUnited Kingdom
-
University Medicine GreifswaldCompletedImpact of OCT1 and CYP2D6 Genotypes on Pharmacokinetics of Berberine in Healthy Volunteers (BERKI-1)Pharmacokinetic Study in Healthy VolunteersGermany
-
Everstar Medicines (Shanghai) LimitedCompletedHealthy Volunteer | Pharmacokinetic StudyChina
-
Bristol-Myers SquibbCompletedPharmacokinetic Study in Healthy ParticipantsUnited States
-
University Medicine GreifswaldNot yet recruitingPharmacokinetic Study in Healthy VolunteersGermany
-
University Medicine GreifswaldRecruitingPharmacokinetic Study in Healthy VolunteersGermany
Clinical Trials on TQ-B3101
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownROS1-positive Non-Small Cell Lung Cancer (NSCLC)China
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownAdvanced Malignant TumorChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownRelapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)China
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownPeripheral T-cell LymphomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed or Refractory Lymphoma or Advanced CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown